Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients

Source: Nasdaq GlobeNewswire / 09 Nov 2022 06:05:00   America/Chicago